Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

EQ

Equillium (EQ)

Equillium Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:EQ
일자시간출처헤드라인심볼기업
2024/12/1406:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
2024/12/1307:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
2024/12/1307:43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EQEquillium Inc
2024/12/1306:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
2024/11/1511:50Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:EQEquillium Inc
2024/11/1406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
2024/11/1406:01Business WireEquillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical UpdatesNASDAQ:EQEquillium Inc
2024/11/1322:00Business WireEquillium to Present at the Stifel Healthcare ConferenceNASDAQ:EQEquillium Inc
2024/11/1222:00Business WireEquillium Announces Poster Presentation at the Society for Immunotherapy of CancerNASDAQ:EQEquillium Inc
2024/11/0101:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EQEquillium Inc
2024/10/3120:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
2024/10/3120:00Business WireEquillium Maintains Rights to Itolizumab Following Ono PartnershipNASDAQ:EQEquillium Inc
2024/10/3109:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
2024/10/3005:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
2024/10/0721:00Business WireEquillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of CancerNASDAQ:EQEquillium Inc
2024/09/1807:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
2024/09/1021:00Business WireEquillium to Present at the Stifel Virtual Inflammation & Immunology SummitNASDAQ:EQEquillium Inc
2024/09/0421:00Business WireEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:EQEquillium Inc
2024/08/2821:00Business WireEquillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor ConferenceNASDAQ:EQEquillium Inc
2024/08/0905:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EQEquillium Inc
2024/08/0905:01Business WireEquillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical HighlightsNASDAQ:EQEquillium Inc
2024/08/0621:00Business WireEquillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host DiseaseNASDAQ:EQEquillium Inc
2024/07/2405:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
2024/07/1903:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
2024/07/1902:57Business WireEquillium Announces Second Quarter 2024 Estimated Cash and Investments BalanceNASDAQ:EQEquillium Inc
2024/07/0221:00Business WireEquillium to Participate in Upcoming Investor ConferencesNASDAQ:EQEquillium Inc
2024/06/1221:00Business WireEquillium to be included in the Russell Microcap® IndexNASDAQ:EQEquillium Inc
2024/06/0521:00Business WireEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:EQEquillium Inc
2024/06/0421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
2024/06/0421:00Business WireEquillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia AreataNASDAQ:EQEquillium Inc
 검색 관련기사 보기:NASDAQ:EQ